Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
Abstract: Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body’s own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases ; volume:5 ; number:4 ; year:2025 ; pages:209-216 ; extent:8
Rheumatology and immunology research ; 5, Heft 4 (2025), 209-216 (gesamt 8)
- Urheber
-
Huang, Hongpeng
Wei, Xuetao
- DOI
-
10.1515/rir-2024-0029
- URN
-
urn:nbn:de:101:1-2501120558136.468746017930
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Huang, Hongpeng
- Wei, Xuetao
Ähnliche Objekte (12)
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
Bispecific antibodies
Bispecific antibodies
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
Novel CD20 monoclonal antibodies for lymphoma therapy
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Intein mediated high throughput screening for bispecific antibodies
Engineering IgG-Like Bispecific Antibodies — An Overview
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
Bispecific antibodies
Bispecific antibodies
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
Novel CD20 monoclonal antibodies for lymphoma therapy
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Intein mediated high throughput screening for bispecific antibodies
Engineering IgG-Like Bispecific Antibodies — An Overview
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
Bispecific antibodies
Bispecific antibodies
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies
Novel CD20 monoclonal antibodies for lymphoma therapy
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Intein mediated high throughput screening for bispecific antibodies